Cydy will get approval for LL for severe patients. That is the game. Not m2m that regeneron got for the 2 drugs for. For those wondering why their drug, see the number of trial participants. More than double our total covid patients m2m plus s2c. THANKFULLY LL has efficacy so its just a matter of numbers of participants now. Btw expecting PR any time that 293 enrollment is done for s2c.
News 
Market Data 
Discover 
AI
